Samsung Bioepis ‘Setting A High Bar’ For Next Wave Of Biosimilars
Korea-Based Company Will Also Target ‘Value-Added Features’
In the wake of parent company Samsung Biologics completing its full acquisition of Samsung Bioepis, the Korea-based biosimilars player has told Generics Bulletin that it will be a “more robust company,” as it applies more rigorous standards to replenishing its pipeline of biosimilar candidates.
